Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
S253272
- Development stage
- Unknown
- Lead developer
- Servier
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
S253272 is an antibody-drug conjugate (ADC) targeting **protein tyrosine kinase 7** (PTK7), also known as colon carcinoma kinase 4 (CCK4). Developed by **Servier**, the agent is designed to deliver a cytotoxic payload specifically to cancer cells overexpressing PTK7, a cell surface protein involved in the Wnt signaling pathway and associated with tumor progression, metastasis, and chemoresistance in various malignancies. The ADC consists of a monoclonal antibody directed against PTK7 conjugated to a cytotoxic agent via a linker. S253272 is currently being evaluated in Phase 1 clinical trials for the treatment of advanced solid tumors, where it aims to provide a targeted therapeutic option by minimizing off-target toxicity while maximizing anti-tumor activity.
- Other names
- PTK7-targeted ADCPTK-7-targeted ADCPTK 7-targeted ADCPTK7 ADCPTK-7 ADCPTK 7 ADC
02
Targets
PTK7 (Protein tyrosine kinase 7)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on S253272.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on S253272.